SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Siegrist, PhD, Executive Vice President of Research & Development and Chief Technology Officer at QuidelOrtho. Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering, driving innovation and next-generation diagnostic solutions. Key insights include: Continue Reading QuidelOrtho Scien ...

BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund’s founder, Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders. The Company issued the following statemen ...

SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the p ...

HENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by Cameron Reynolds, Group Chief Executive Officer As 2025 draws to a close, I would like to take this opportunity to look back on the year's key milestones and look to the opportunities ahead. Before diving into the detail, I would like to take a moment to reflect on our founding mission. We set out over fifteen year ...

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, tit ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor's nationwide expansion and broaden patient access to its immunotherapy-response diagnostics. Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 states, representing more than $100. ...

Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech’s competitive position in the $2B+ HbA1c market DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, tod ...

公司股息政策更新 - 公司董事会宣布将季度普通股股息提高至每股0.63美元，增幅为6.8% [1] - 自2020年以来，公司的季度股息支付总额已增长超过70% [1][4] - 此次是公司连续第54年实现股息增长，也是自1924年以来连续第408个季度支付股息 [1][4] 公司市场地位与历史 - 公司是标普500股息贵族指数的成员，该指数追踪那些至少连续25年每年增加股息的公司 [2] - 公司是一家全球医疗健康领域的领导者，业务涵盖诊断、医疗器械、营养品和品牌仿制药 [3] - 公司拥有114,000名员工，业务遍及全球超过160个国家 [3] 股息支付安排 - 增加的现金股息将于2026年2月13日支付给在2026年1月15日营业时间结束时登记在册的股东 [1]

Key Takeaways Hologic's Diagnostics revenue rose in Q4 on stronger U.S. molecular testing and 4.4% organic growth.Molecular Diagnostics led gains, fueled by Hologic's BV CV/TV and Panther Fusion assay momentum.HOLX broadened its Diagnostics lineup with EU expansion for Genius and new Panther Fusion assays.Hologic (HOLX) offers a wide range of diagnostic products to help in the screening and diagnosis of human disease. Although the performance of the Diagnostics segment in recent quarters has been impacted b ...

文章核心观点 - Castle Biosciences公司宣布其TissueCypher® Barrett's Esophagus测试的一项新的系统综述和荟萃分析结果发表 该分析证实该测试能为巴雷特食管患者提供临床验证的风险分层 在识别食管癌高风险患者方面优于传统的病理学或临床因素 [1] 产品技术与临床验证 - 该研究论文发表在《Journal of Clinical Gastroenterology》上 整合了六项已发表研究的数据 证实TissueCypher能一致性地识别出进展为高级别不典型增生或食管腺癌风险更高的患者 [2] - 系统综述和荟萃分析代表了严谨、高质量的临床验证证据 此次分析结果是迄今为止对TissueCypher测试最全面的验证 巩固了其作为巴雷特食管循证风险分层工具的价值 [3] - 该测试采用人工智能驱动的空间组学方法 识别通常在发育不良之前出现的分子特征 从而能更早地识别、治疗和管理癌症风险增加的患者 [7] - TissueCypher测试已获得17篇同行评审出版物的支持 并在超过8,000名患者的活检样本中进行了研究 被证明是相比传统组织病理学风险评估最强的独立预测因子 [7] 关键临床数据发现 - 综合六项研究数据 高风险TissueCypher结果的患者在五年内进展为高级别不典型增生或食管腺癌的可能性是低风险结果患者的6.7倍 [9] - 具有高风险或中等风险结果患者的年进展率为2.8% 其中高风险结果患者的年进展率为5.6% 均高于通常报告的低级别不典型增生患者的年进展率基准1.7% [9] - 该测试的预测性能在无非典型增生、不典型增生不确定和低级别不典型增生的患者中均得到证实 并且在识别最高风险患者方面优于组织学评估 [3] 产品应用与市场定位 - TissueCypher是一种精准医学测试 旨在预测巴雷特食管患者进展为高级别不典型增生或食管腺癌的个性化风险 适用于无非典型增生、不典型增生不确定或低级别不典型增生的患者 [6] - 该测试旨在通过分析标准食管穿刺活检 无缝整合到常规内镜实践中 无需额外操作即可提供可操作的见解 [7] - 通过识别哪些患者真正处于高风险 哪些不是 该测试可帮助医生个性化护理 标记可能受益于早期干预的患者 并为低风险患者继续常规监测提供信心 [3] - 该分析证实TissueCypher提供一致、可重复的性能 支持其帮助医生提供风险匹配护理的潜力 识别最可能进展的患者并定制管理策略 从而改善结果并减少不必要的程序 [5] 公司背景 - Castle Biosciences是一家领先的诊断公司 通过指导患者护理的创新测试来改善健康 主要专注于皮肤科和胃肠疾病领域 开发个性化的、临床可操作的解决方案以帮助改善疾病管理和患者结局 [10]